Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Apr;39(4):924–929. doi: 10.1128/aac.39.4.924

Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice.

J R Graybill 1, L K Najvar 1, J D Holmberg 1, M F Luther 1
PMCID: PMC162655  PMID: 7785997

Abstract

D0870 is a recently developed triazole with characteristics of a broad spectrum of activity and slow clearance by nonrenal mechanisms. Herein we have evaluated the efficacy of D0870, alone and combined with flucytosine, in a murine model of disseminated Candida tropicalis infection. Four isolates of C. tropicalis were evaluated. Two were highly susceptible in vitro to fluconazole, and two were resistant to fluconazole. All were highly susceptible to flucytosine and D0870. Animals were pretreated with 5-fluorouracil 1 day before infection because C. tropicalis has reduced virulence in immunocompetent mice. This was done to render them neutropenic for > 10 days. Mice were infected intravenously and treated orally with D0870 or fluconazole, alone or combined with flucytosine. Survival and tissue burden of the spleen and kidneys were used to evaluate the efficacy of antifungal therapy. Fluconazole was less effective for treatment of resistant C. tropicalis than susceptible C. tropicalis. D0870 was more potent than fluconazole and was effective in fluconazole-resistant isolates. Flucytosine was consistently effective when used alone but did not consistently add to the benefit of D0870 or fluconazole. D0870 has potential in treatment of candidiasis caused by C. tropicalis, including fluconazole-resistant isolates.

Full Text

The Full Text of this article is available as a PDF (181.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allendoerfer R., Marquis A. J., Rinaldi M. G., Graybill J. R. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother. 1991 Apr;35(4):726–729. doi: 10.1128/aac.35.4.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Edwards J. E., Jr, Filler S. G. Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S106–S113. doi: 10.1093/clinids/14.supplement_1.s106. [DOI] [PubMed] [Google Scholar]
  3. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Wingard J. R., Merz W. G., Saral R. Candida tropicalis: a major pathogen in immunocompromised patients. Ann Intern Med. 1979 Oct;91(4):539–543. doi: 10.7326/0003-4819-91-4-539. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES